Insider Shareholders with Direct Ownership of I Teos Therapeutics, Inc. (ITOS)
This section provides a comprehensive overview of the insiders with direct ownership of I Teos Therapeutics, Inc. (ITOS). You can find detailed information about the size and nature of each insider's ownership stake, as well as the latest updates on their holdings.
iTeos Therapeutics, Inc. Insider List
| Insider | Adquired | Disposed | Held | # of Trades | Last Transaction |
|---|---|---|---|---|---|
| 5,560,116 | 1,625,201 | 2,946,915 $43.7 Million | 6 |
May 10, 2024
Added 27.94%
|
|
|
Matthew Call
Chief Operating Officer |
137,898 | 0 | 137,898 $2.05 Million | 3 |
Dec 05, 2023
Added 24.19%
|
|
Matthew Gall
Chief Financial Officer |
65,429 | 5,000 | 60,429 $896,766 | 5 |
Dec 05, 2023
Added 40.42%
|
|
Michel Detheux
Chief Executive Officer |
97,763 | 219,437 | 58,903 $874,120 | 32 |
Dec 05, 2023
Added 33.74%
|
|
Yvonne Mc Grath
Chief Scientific Officer |
72,707 | 41,707 | 31,000 $460,040 | 13 |
Dec 05, 2023
Added 50.0%
|
| 79,615 | 79,615 | 0 $0 | 6 |
Jun 09, 2022
Reduced 100.0%
|
|
|
Detlev Biniszkiewicz
Director |
3,500 | 3,500 | 0 $0 | 2 |
Jan 03, 2022
Reduced 100.0%
|
|
Joanne Jenkins Lager
Chief Medical Officer |
56,000 | 56,000 | 0 $0 | 14 |
Mar 11, 2022
Reduced 100.0%
|